Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 3, 2025
Podoplanin-TGF-β1 Autocrine Loop: Pivotal Regulator of Islet Stellate Cell Activation via Cell Deformation, Orchestrating Islet Fibrosis in DiabetesXiaohang Wang, Qianqian Wang, Yang Yuan, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 22, 2023
Long-term exercise preserves pancreatic islet structure and β-cell mass through attenuation of islet inflammation and fibrosisVladmir H C Carvalho, Qianqian Wang, Xiaohan Xu, et al.
Stem Cell Research & Therapy|August 12, 2021
Mesenchymal stem cell-derived exosomal miR-146a reverses diabetic β-cell dedifferentiationQin He, Jia Song, Chen Cui, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 4, 2025
Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trialYijie Ma, Zhi Li, Chen Wei, et al.
BMC Endocrine Disorders|October 30, 2024
Association between night blindness history and risk of diabetes in the Chinese population: a multi-center, cross sectional studyJinbang Wang, Yunting Zhou, Yu Liu, et al.
Molecular and Cellular Endocrinology|August 31, 2021
Mesenchymal stem cell-conditioned medium alleviates high fat-induced hyperglucagonemia via miR-181a-5p and its target PTEN/AKT signalingJia Song, Qin He, Xinghong Guo, et al.
Nature|March 25, 2021
REV-ERB in GABAergic neurons controls diurnal hepatic insulin sensitivityGuolian Ding, Xin Li, Xinguo Hou, et al.
Clinical and Translational Medicine|April 30, 2024
Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trialYuzhou Zhao, Danyang Li, Jing Zhuang, et al.
Pageof 4